NewslettersHepatic Cell NewsHuman Immunology NewsSitravatinib Targets TYRO3 to Augment the Anti-Tumor Immune Response of PD-1 Blockade in Hepatocellular CarcinomaBy Jamie Kang - May 13, 20250434Scientists investigated the anti-tumor efficacy and immunomodulatory activity of sitravatinib in hepatocellular carcinoma.[Clinical Cancer Research]Abstract